Willing AR, Fontaine G, Treloar C, Silk D, Grebely J, & Marshall AD. The International journal on drug policy. 2026, 148, 105131. https://doi.org/10.1016/j.drugpo.2025.105131
Our team, led by Dr. Guillaume Fontaine at McGill University, is working on improving healthcare delivery and outcomes through rigorous implementation research.
The RISE³ LAB conducts quantitative, qualitative, and mixed-methods implementation research to improve healthcare delivery and outcomes. By focusing on the integration of evidence-based practices into real-world settings, the lab aims to ultimately improve the quality and equity of healthcare and enhance health outcomes. Our research spans a number of clinical areas, including infectious diseases, cancer care, and mental health care.
Dr. Fontaine is a Tenure-Track Assistant Professor of Implementation Science in the Ingram School of Nursing at McGill University, and a Principal Investigator at the Centre for Clinical Epidemiology of the Lady Davis Institute. He holds a FRQS Junior 1 Research Scholar Award. He is the National Co-Lead of Implementation Science in the CIHR Canadian Network on Hepatitis C (CanHepC), and the National Co-Lead of Methods in the CIHR Canadian HIV and STBBIs Clinical Trials Research Network (CTN+).
Willing AR, Fontaine G, Treloar C, Silk D, Grebely J, & Marshall AD. The International journal on drug policy. 2026, 148, 105131. https://doi.org/10.1016/j.drugpo.2025.105131
Cunningham EB, Wheeler A, Hajarizadeh B, French CE, Roche R, Roth M, Willing A, Sazzad H, Marshall AD, Fontaine G, Conway A, Valencia BM, Presseau J, Ward JW, Degenhardt L, Dore GJ, Hickman M, Vickerman P, Lafferty L, Lloyd A, Sheehan Y, Akiyama MJ, Kronfli N, Cabezas J, & Grebely J. International journal on drug policy. 2026, 149, 105082. https://doi.org/10.1016/j.drugpo.2025.105082
